Phase II
Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous C5 and Leukotriene B4 (LTB4) Activity
Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent on Monday after the company provided an updated look at its gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
Linzagolix overall efficacy and safety maintained or improved at week 24
Updated data show continued reductions in body weight and decreased appetite in patients with rare genetic disorders of obesity
Allergy Therapeutics plc today announces preliminary results for the year ended 30 June 2018.
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
GlaxoSmithKline (GSK) and the non-profit Aeras reported that their M72/AS01E vaccine candidate significantly cut the rate of pulmonary tuberculosis in HIV-negative adults with latent tuberculosis infection.
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
PRESS RELEASES